Compare ERH & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERH | NTHI |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5M | 106.0M |
| IPO Year | N/A | 2023 |
| Metric | ERH | NTHI |
|---|---|---|
| Price | $10.21 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 21.1K | ★ 177.7K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.16 | $2.96 |
| 52 Week High | $13.07 | $12.99 |
| Indicator | ERH | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 31.68 | 43.54 |
| Support Level | N/A | $3.03 |
| Resistance Level | $11.69 | $3.70 |
| Average True Range (ATR) | 0.15 | 0.34 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 22.02 | 36.84 |
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.